Anti-Diabetic Drug Utilization and Assessment of Glycemic Control Using Glycated Hemoglobin in Patients with Diabetes Mellitus Attending a Tertiary Hospital in South-West Nigeria
Diabetes Mellitus is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. This study focuses on antidiabetic drug utilization and assessment of glycemic control using glycated hemoglobin in patients with diabetes. This was a prospective cross-sectional study carried out from August to November 2015 in the University College Hospital, Ibadan. Data were collected from patients’ case notes for drug utilization study and an assessment of glycemic level using glycated hemoglobin (HbA1c) was executed, patients were interviewed for socio-demographic data and adherence. Data were analyzed and interpreted using SPSS 13 version. A total of 201 case notes were reviewed. Female patients made 67.16% and male 32.84%. Average age range was 60 – 69 years. Average number of drugs per encounter was 2.7 and 87.3% of the drugs were prescribed by their generic names. Percentage encounter containing antibiotics and injections were 3.7% and 13.4% respectively, 92.5% of drugs prescribed were from the essential drug list, others include: antidiabetics 175 (32.6%), Antihypertensive 175 (32.7%), non-steroidal anti-inflammatory drugs 45 (8.4%), statins 40 (7.5%), vitamins 13 (2.4%), antibiotics 20 (3.7%), central nervous system drugs 9 (1.7%), others 59 (11.0%). The most prescribed antidiabetic drug was the biguanides (B) occurring in 23.38%. B plus sulfonylureas (SU) were the most prescribed combinations occurring in 30.35% of prescription. SU showed most effective glycemic control of 60% compared to B, 53.3% or its combination, not statistically significant (P>0.05). This reveals a rational drug use pattern and good compliance to drug therapy
Akinkingbe, O.O. 1997. Non-communicable Diseases in Nigeria: National Survey (Final Report) on Hypertension, Coronary Heart Disease, Diabetes mellitus, Haemoglobinopathy, G6PD Deficiency and Anaemia National Expert Committee on Non-Communication Disease. Federal Ministry of Health and Social services. Lagos. The Nigeria Health Journal Vol. 11, No 4.
American Diabetes Association (ADA). 2012. Diagnosis and Classification of Diabetes Mellitus. Diabetes care, volume 35, supplement 1, january.
British Medical Association and Royal Pharmaceutical Society of Great Britain (BMARPSGB). 2003. British National Formulary (BNF), 46th edition, pharmaceutical Press (Pub), U.K. pp. 62-69, 123-129, 326-341.
Cantrill, J.A. 1999. Diabetes Mellitus In: Walker, R., and C. Edward. Text Book of Clinical Pharmacy and Therapeutics, 2nd edition, Mc Graw-Hill companies Inc., USA, 633-652.
Enwere, O.O., B.L. Salako, and C.O. Falade. 2006. Prescription and Cost Consideration at a Diabetic Clinic in Ibadan, Nigeria: A Report. Annals of Ibadan Postgraduate Medicine; Vol.4 No2 Dec.
Gribble, F.M., and F. Reiman. 2003. Sulphonylurea action revisited: the post cloning era. Diabetologia; 46: 875-891
Johnson, J.A., S.L. Pohar, and K. Secnik. 2001. Utilization of diabetes medication and cost of testing supplies in Saskatchewan. BMC Health Serv Res.; 6:159.
Krishmnamurti, U., and M.W. Steffes. 2001. Glycohemoglobin: A primary predictor of the development or reversal of complications of diabetes mellitus. Clinical chemistry;47:1157-65.
Larsen, M.L., M. Harder, and E.F. Mogensen. 1990. Effect of long-term monitoring of glycosylated hemoglobin levels in insulin-dependent diabetes mellitus" N. Engl. J. Med.323(15):1021-5.
Lau, G.S.N., J.C.N. Chan, P.L.M. Chu, D.C.K. Tse, and J.A.J.H. Critchley. 1996. Use of antidiabetic and antihypertensive drugs in hospital and outpatient settings in Hong Kong. Ann Pharmacother.;30:232-7.
Motala, A.A. 2002. Diabetes trends in Africa Diabetes. metab Res Rev; 18:514-520.
Ontarget Investigators, S. Yusuf, K.K. Teo, J. Pogue, and L. Dyal. 2008. Telmisartan, ramipril or both in patients at high risk forvascular events. N. Engl. J. Med., 358; 1547-1559
Practitioner’s manual. 2006. Valid prescription requirements. U. S. Department of justice, Drug enforcement administration. www.Justice. Gov/dea/index.htm
Qaseem, A. 2012. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med, 156(3): p. 218-31.
Sicree, R., J. Shaw, and P. Zimmet. 2006. Diabetes and impaired glucose tolerance in India. Diabetes Atlas. Gan D Ed. International Diabetes Federation, Belgium. Pp15-103.
Sivasankari, V., E. Manivannan, and S.P. Priyadarsini. 2013. Drug utilization pattern of anti-diabetic drugs in rural area of Tamilnadu, South India – A prospective, observational study” Int J Pharm Bio Sci Jan; 4(1): (P)514 – 519.
Sultana, G., P. Kapur, M., and Aqil, M. 2010. Drug utilization of oral hypoglycemic agents in a university teaching hospital in India. J Clin Pharm Ther;35(3):267-77.
Upadhyay, D.K., S. Palaian, and P. Ravi Shankar. 2007. Prescribing Pattern In Diabetic Outpatients In A Tertiary Care Teaching Hospital In Nepal. Journal of Clinical and Diagnostic Research; 3:248-55.
Wild, S., G. Roglic, A. Green, R. Sicree, and H. King. 2004. Global prevalence of Diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care; 27:1047-1053.
World Health Organization (WHO). 1997. The selection of essential drugs.WHO Tech Rep; 615: 36.
World Health Organization (WHO). 2011. WHO Diabetes Fact Sheet, August 2011. July, Available from: http://www.who.int/mediacentre/factsheets/fs312/en/index.html
Yurgin, N., K. Secnik, and M.J. Lage. 2007. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study. Clin Ther;29(2):316-25